Peregrine Ventures ups fundraising ante as it hits first close for debut growth fund
Israel-based early stage investor Peregrine Ventures has hit a first close for a $300m-targeting growth fund focused on late stage life science companies.
Israel-based early stage investor Peregrine Ventures has hit a first close for a $300m-targeting growth fund focused on late stage life science companies.
Recent Comments